A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 12, 2018

Study Completion Date

September 12, 2018

Conditions
Small Cell Lung Carcinoma
Interventions
DRUG

Rovalpituzumab Tesirine

Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)

Trial Locations (15)

14263

Roswell Park Cancer Institute, Buffalo

29605

Greenville Health System Cancer Institute, Greenville

30322

Winship Cancer Institute, Emory University, Atlanta

40503

Baptist Health Lexington, Lexington

44106

University Hospitals Case Medical Center, Cleveland

44109

MetroHealth Medical Center, Cleveland

45267

University of Cincinnati, Cincinnati

46845

Parkview Research Center, Fort Wayne

48201

Karmanos Cancer Institute, Detroit

48202

Henry Ford Hospital, Detroit

60637

University of Chicago Medical Center, Chicago

75230

Mary Crowley Medical Research Center, Dallas

90404

University of California Los Angeles, Los Angeles

T6G 1Z2

Cross Cancer Institute, Edmonton

K1H 8L6

The Ottawa Hospital-Cancer Centre, Ottawa

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Stemcentrx

INDUSTRY